Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad pipeline across kidney disease, neuropathic pain, type 1 diabetes and other serious conditions. The VRTX news feed on Stock Titan brings together company press releases and other coverage that highlight how its commercial portfolio and research programs are evolving over time.
News about Vertex often focuses on clinical data readouts, regulatory milestones and commercial updates. Recent announcements have covered progress in cystic fibrosis, including data on ALYFTREK and other CFTR modulators presented at scientific conferences, and updates on next-generation CFTR correctors and CFTR mRNA therapies. Vertex also regularly reports on CASGEVY, its CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, including longer-term outcomes data and plans for regulatory submissions in additional age groups.
Investors and followers of VRTX news can also expect updates on JOURNAVX, the company’s oral non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in adults, including information on prescription trends, payer coverage and hospital formulary adoption. In kidney diseases, Vertex issues news on povetacicept and inaxaplin, including Phase 1/2 and Phase 3 trial data in IgA nephropathy, primary membranous nephropathy and APOL1-mediated kidney disease, as well as regulatory designations such as Breakthrough Therapy and Fast Track.
Additional news items may include financial results, participation in major healthcare investor conferences, and updates on programs in type 1 diabetes, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. For anyone tracking VRTX stock, this news page offers a centralized view of how Vertex’s marketed products and pipeline advance through clinical development, regulatory review and commercialization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vertex Pharmaceuticals (NASDAQ: VRTX) has received FDA approval to extend the use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor) for children aged 2 to 5 years with cystic fibrosis (CF) who possess at least one F508del mutation.
This marks a significant milestone, as approximately 900 children will now have access to a treatment targeting the underlying cause of their disease. This approval was backed by a 24-week Phase 3 study involving 75 children, showing a well-tolerated safety profile and improved lung function metrics.
TRIKAFTA, previously authorized for patients aged 6 and older, has transformed CF management and is expected to continue benefiting the CF community globally as Vertex seeks additional approvals in other regions.
Vertex Pharmaceuticals (NASDAQ: VRTX) has announced its participation in the Bank of America Securities 2023 Health Care Conference, scheduled for May 9, 2023, at 9:20 a.m. PT / 12:20 p.m. ET. The conference will feature a management presentation, and a live webcast will be accessible via the company’s website, specifically in the 'Investors' section under 'News and Events'. A replay of the presentation will also be archived on the site.
Vertex is a leading biotechnology company focused on innovative medicines for serious diseases, primarily known for its successful treatments for cystic fibrosis. The company is headquartered in Boston and has a global presence with multiple clinical programs addressing serious conditions such as sickle cell disease and type 1 diabetes. For further information, visit www.vrtx.com.
Vertex Pharmaceuticals (NASDAQ: VRTX) is set to report its Q1 2023 financial results on May 1, 2023, after market close. A conference call will follow at 4:30 p.m. ET, allowing participants to dial in for insights on the earnings announcement. Vertex is renowned for its innovative treatments for cystic fibrosis and has a diverse pipeline of investigational therapies targeting serious diseases such as sickle cell disease and type 1 diabetes. The call will also be available via webcast on the Vertex website, with an archived version accessible later. Founded in 1989, Vertex has consistently earned recognition as a top employer and continues to advance its commitment to transformative medicine.
Vertex Pharmaceuticals and CRISPR Therapeutics have completed the rolling Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) aimed at sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The applications, submitted to the FDA, include requests for Priority Review, potentially expediting the review period to eight months. The filings are supported by ongoing Phase 3 clinical studies and previous data presented at the ASH Annual Meeting in December 2022. Both companies highlight their commitment to the advancement of CRISPR technology in treating genetic diseases.
Vertex Pharmaceuticals has secured a non-exclusive licensing agreement with CRISPR Therapeutics for its CRISPR/Cas9 technology, aiming to enhance the development of hypoimmune cell therapies for Type 1 Diabetes (T1D). Vertex will pay
FAQ
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
What is the market cap of Vertex Pharmaceuticals (VRTX)?
